Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- With Right Infrastructure, “Bright Future”for Multinational Trials: Mr Morimoto of CMIC
July 4, 2011
- Sosei Group to Collaborate with Gifu Pharm. Univ.
July 4, 2011
- Korosho Instructs Revision of Package Inserts for Pioglitazone
July 4, 2011
- Korosho to Select 5 Hub Med. Institutions for Early-stage Clinical Studies
July 4, 2011
- Tsuruha HD: Dispensing Fees Up 10.2% in FY2010
July 4, 2011
- EMA to Issue Conclusion on Bladder Cancer Risk from Actos in July
July 4, 2011
- AnGes MG Obtains Patent on HVJ-E for Cancer
July 4, 2011
- R&I Upgrades Kaken's Rating from “Stable”to “Positive”
July 4, 2011
- Takeda Applies for SGN-35 in Europe
July 4, 2011
- Current Users to Be Permitted to Rely on Telemarketing to Buy Reclassified Class 2 OTC Drugs
July 4, 2011
- R&I Keeps AA- Rating for Eisai
July 4, 2011
- Merck Serono Stops Global Approval Process for Cladribine
July 4, 2011
- 3 Groups Reconfirm Opposition to Deregulating Online Sale of OTC Drugs
July 4, 2011
- Mebiopharm to Be Listed on TOKYO AIM on July 15
July 4, 2011
- Largest No. of New Drugs Listed in FY2010 in the Past 15 Years: FPMAJ
July 4, 2011
- JPA Presents Its Opinions on OTC Drug Risk Reclassification to Korosho
July 4, 2011
- Combined Sales of 23 Japanese Drug Companies Reach ¥100 billion in China
July 4, 2011
- Nihon Chouzai to Invest ¥10 Bil. to Increase GE Production Capacity
July 4, 2011
- Anticancer Drug Market in Japan to Exceed ¥1 Tril. in 2019: Fuji-Keizai
July 4, 2011
- Pfizer Japan to Promote Established Products with Force of 1,000
July 4, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…